Akcje Novartis AG (NVS) — czy to dobra firma?

Akcje Novartis AG (NVS) — czy to dobra firma? — InspectStocks

Jak zarabia

Prescription medicines

Konkuruje z

Co sprzedaje6

Entresto
A pill used to treat certain types of chronic heart failure, when the heart cannot pump or fill with blood properly.
Cosentyx
An injection for inflammatory conditions including psoriasis, some forms of arthritis and a chronic skin disease called hidradenitis suppurativa.
Kisqali
A cancer medicine used with hormone treatment for certain types of breast cancer.

Pokaż 3 więcej

Kesimpta
A monthly self-injection for adults with relapsing forms of multiple sclerosis, a disease in which the immune system damages nerves.
Pluvicto
An intravenous treatment that delivers radioactive particles to certain prostate cancer cells.
Leqvio
An injection given by a health professional to lower low-density lipoprotein (LDL) cholesterol, a type of fat in the blood.

Kto to kupuje5

Drug wholesalers buy medicines for resale to pharmacies and healthcare providers.
Retail and specialty pharmacies dispense medicines to patients, including drugs that need special handling.
Hospitals and private health systems buy medicines for treatment in their facilities.

Pokaż 2 więcej

Government agencies and government-supported health systems buy or fund medicines for patients.
Insurers and managed-care organizations influence which medicines are covered and reimbursed.

Na czym się opiera i co może to zburzyć

Od czego zależy ta działalność

1Sales of branded medicines depend on patent rights and regulatory exclusivity; generic or biosimilar competitors can enter after protections expire or are successfully challenged.
2Some medicines depend on licenses, collaborations or other agreements with outside drug developers.
3Manufacturing depends on specialized materials and tightly controlled production processes; some products may have limited alternative suppliers.
4Access to medicines depends on health-authority approval and on insurers or government health systems deciding whether and how much to reimburse.

Co może pójść nie tak

1Generic competition and patent challenges can reduce sales when drug protections expire or competitors successfully challenge them; Novartis has also faced generic erosion for established medicines.
2Government price controls, Medicare price negotiations, required rebates and insurer coverage decisions can limit the prices Novartis receives or restrict patient access.
3Drug candidates can fail clinical trials or fail to receive approval after years of research and testing, leaving Novartis without a marketable medicine and with development costs already incurred.

Pełne sprawozdania finansowe →

O spółce Novartis AG

Novartis researches, tests, manufactures and sells prescription medicines in about 120 countries (2025, high). Its research focuses on heart, kidney and metabolic diseases, immune disorders, brain and nerve diseases, and cancer. Net sales were USD 54.532 billion (FY2025, high).

Siedziba: Basel, Switzerland
Rok założenia: 1996
Zatrudnienie: 75,267 (December 31, 2025, high)
Notowana na: NYSE
Koniec roku obrotowego: December 31

Zbudowane z własnych raportów spółki Novartis AG składanych do amerykańskiej Komisji Papierów Wartościowych i Giełd (SEC). Liczby są takie, jak zaraportowano, a historia na akcję przeliczona na dzisiejszą bazę akcji. To opisuje firmę — nie jest poradą inwestycyjną ani rekomendacją kupna lub sprzedaży.

Keep exploring

The themes Novartis is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Highest-graded in Drug Manufacturers General

Graded A or B and worth $2B or more: A first, then the largest.

All 19 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Jak zarabia

Prescription medicines

Konkuruje z

Co sprzedaje6

Entresto
A pill used to treat certain types of chronic heart failure, when the heart cannot pump or fill with blood properly.
Cosentyx
An injection for inflammatory conditions including psoriasis, some forms of arthritis and a chronic skin disease called hidradenitis suppurativa.
Kisqali
A cancer medicine used with hormone treatment for certain types of breast cancer.

Pokaż 3 więcej

Kesimpta
A monthly self-injection for adults with relapsing forms of multiple sclerosis, a disease in which the immune system damages nerves.
Pluvicto
An intravenous treatment that delivers radioactive particles to certain prostate cancer cells.
Leqvio
An injection given by a health professional to lower low-density lipoprotein (LDL) cholesterol, a type of fat in the blood.

Kto to kupuje5

Drug wholesalers buy medicines for resale to pharmacies and healthcare providers.
Retail and specialty pharmacies dispense medicines to patients, including drugs that need special handling.
Hospitals and private health systems buy medicines for treatment in their facilities.

Pokaż 2 więcej

Government agencies and government-supported health systems buy or fund medicines for patients.
Insurers and managed-care organizations influence which medicines are covered and reimbursed.

Na czym się opiera i co może to zburzyć

Od czego zależy ta działalność

1Sales of branded medicines depend on patent rights and regulatory exclusivity; generic or biosimilar competitors can enter after protections expire or are successfully challenged.
2Some medicines depend on licenses, collaborations or other agreements with outside drug developers.
3Manufacturing depends on specialized materials and tightly controlled production processes; some products may have limited alternative suppliers.
4Access to medicines depends on health-authority approval and on insurers or government health systems deciding whether and how much to reimburse.

Co może pójść nie tak

1Generic competition and patent challenges can reduce sales when drug protections expire or competitors successfully challenge them; Novartis has also faced generic erosion for established medicines.
2Government price controls, Medicare price negotiations, required rebates and insurer coverage decisions can limit the prices Novartis receives or restrict patient access.
3Drug candidates can fail clinical trials or fail to receive approval after years of research and testing, leaving Novartis without a marketable medicine and with development costs already incurred.

Pełne sprawozdania finansowe →

O spółce Novartis AG

Siedziba: Basel, Switzerland
Rok założenia: 1996
Zatrudnienie: 75,267 (December 31, 2025, high)
Notowana na: NYSE
Koniec roku obrotowego: December 31

Jak zarabia

Konkuruje z

Co sprzedaje6

Kto to kupuje5

Na czym się opiera i co może to zburzyć

Od czego zależy ta działalność

Co może pójść nie tak

O spółce Novartis AG

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Jak zarabia

Konkuruje z

Co sprzedaje6

Kto to kupuje5

Na czym się opiera i co może to zburzyć

Od czego zależy ta działalność

Co może pójść nie tak

O spółce Novartis AG

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Big pharma

Novartis AG

Wzrost i gotówka — 5 z 5

Cena akcji i ocena w czasie

Jak zarabia

Konkuruje z

Co sprzedaje6

Kto to kupuje5

Na czym się opiera i co może to zburzyć

Od czego zależy ta działalność

Co może pójść nie tak

O spółce Novartis AG

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Jak zarabia

Konkuruje z

Co sprzedaje6

Kto to kupuje5

Na czym się opiera i co może to zburzyć

Od czego zależy ta działalność

Co może pójść nie tak

O spółce Novartis AG

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Big pharma

Novartis AG

Wyniki historyczne

Wzrost i gotówka — 5 z 5

Cena akcji i ocena w czasie